Why do some mature-TLS lung cancers resist immunotherapy? Two CAF subsets that drive primary resistance in NSCLC
Can blocking PRMT5 starve sarcomas of energy? Inhibiting the enzyme shuts down tumor glycolysis and growth
Profiling of immune cell components and soluble factors in ovarian cancer ascites highlights impaired immune environment
Background Ovarian cancer ascites are increasingly recognized as important contributors to ovarian cancer progression. The behavior of tumor cells is strongly influenced by the composition of their surrounding microenvironment. Characterizing the cellular and soluble composition of ascites is therefore essential to better understand how this specific milieu affects tumor progression. In particular, ascites may contribute […]
How tolerogenic cDC1 dendritic cells “educate” inflammatory cDC2 by exporting the tryptophan metabolite L-kynurenine
Ovarian cancer ascites display altered immune environment featured by enhanced soluble factors and suppressive cellular context
Background The tumor microenvironment of epithelial ovarian cancer is unique among solid tumors, as tumor cells can shape their own microenvironment through the formation of malignant ascites. These ascites represent a complex mixture of soluble factors and cellular components. They are known to be enriched in macrophages, which have been suggested to acquire an M2-like […]
Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
Background In the era of immuno-oncology, identifying primary resistance mechanisms to immune checkpoint inhibitors remains crucial. A better understanding of these mechanisms may help to identify novel pathways that can be targeted to improve response rates, as well as biomarkers that could support the selection of patients more likely to benefit from cancer immunotherapies. Among […]
Why IDO1 inhibitors failed in the clinic — and what’s next for targeting tryptophan metabolism in cancer
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
How CD95 keeps NF-κB switched off in triple-negative breast cancer — and what its loss unleashes
How CD95/Fas helps triple-negative breast cancer escape NK-cell control in preclinical models
